Investment Info

Urologix, Inc., based in Minneapolis, is the leading provider for in-office BPH therapy. The company develops, manufactures, markets and distributes minimally invasive medical products for BPH treatment. Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.

Urologix' patented Cooled ThermoTherapy™ technology is creating effective treatment options for a wide range of patients with BPH. Cooled ThermoTherapy delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue and enhances patient comfort.

Prostiva® RF Therapy provides direct visualization with 360 degrees of precision which allows the urologist to treat the median and lateral lobe as well as asymmetrical prostates. This system is able to reach intraprostatic temperatures of 110°C allowing it to create a lesion in the tissue causing significant necrosis in just two minutes and 20 seconds. Experienced physicians report good patient tolerability with the utilization of a prostate block.

Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

¹Data on file at Urologix, Inc.

Stock Quote
ULGX (Common Stock)
ExchangeOTCQB (US Dollar)
Financial Status IndicatorN
Change (%) Stock is Up 0.01 (12.50%)
Data as of 04/06/15 9:56 a.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
Download Documentation 2014 Annual Report
Recent NewsMore >>
07/09/15Urologix Announces SEC Deregistration
MINNEAPOLIS, July 09, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH,  today announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission (the “SEC”). The Company also intends to cause its common stock to cease trading on the OTCQB and commence trading on the OTC Pink marketplace.  For more information about the OTC Pink marketpla... 
Printer Friendly Version
05/21/15Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans
MINNEAPOLIS, May 21, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc.  (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data highlighting the costs and outcomes of cooled high energy Transurethral Microwave Therapy (HE-TUMT), Transurethral Needle Ablation (TUNA), and the Prostatic Urethral Lift (PUL) were the topic of a podium presentation this past weekend at the American Urological Association (AUA) 2015 Annual Meeting held in New Or... 
Printer Friendly Version
05/12/15Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans
American Urological Association Meeting 2015 MINNEAPOLIS, May 12, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an upcoming presentation at the American Urological Association (AUA) 2015 annual meeting to be held May 15-18, 2015 in New Orleans, LA. The podium presentation (Abstract #PD16-09) “Healthcare Costs for Office Based Benign Prostatic Hyperplasia Therapies” was s... 
Printer Friendly Version
05/12/15Urologix Reports Third Quarter Fiscal Year 2015 Results
Recent Quarter Results Revenue $2.8 Million Ending cash balances, including restricted cash of $532,000 $2.8 million owed under the Prostiva license and Medtronic promissory note remains past due Cost-effectiveness of Urologix products being presented at 2015 American Urological Association annual meeting MINNEAPOLIS, May 12, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of B... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Urologix, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.